Suppr超能文献

成人多发性硬化症预后因素的细化:当前见解的叙述性综述

Refining Prognostic Factors in Adult-Onset Multiple Sclerosis: A Narrative Review of Current Insights.

作者信息

Guerra Tommaso, Copetti Massimiliano, Achille Mariaclara, Ferri Caterina, Simone Marta, D'Alfonso Sandra, Pugliatti Maura, Iaffaldano Pietro

机构信息

Department of Translational Biomedicine and Neurosciences-DiBraiN, University of Bari "Aldo Moro", Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, 70100 Bari, Italy.

Unit of Biostatistics, Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.

出版信息

Int J Mol Sci. 2025 Aug 11;26(16):7756. doi: 10.3390/ijms26167756.

Abstract

Multiple sclerosis (MS) is characterized by a continuum of diverse neuroinflammatory and neurodegenerative processes that contribute to disease progression from the earliest stages. This leads to a highly heterogeneous clinical course, requiring early and accurate prognostic assessment: the identification of reliable prognostic biomarkers is crucial to support therapeutic decision-making and guide personalized disease management. In this narrative review, we critically examined the current MS literature, investigating prognostic factors associated with disease progression and irreversible disability in adult-onset MS, with a focus on different clinical, radiological, and molecular biomarkers. Particular attention is directed toward the prognostic value of baseline clinical and neuroimaging factors, emerging biomarkers of smoldering disease, and progression independent of relapse activity (PIRA) events. Additionally, we discussed the role of integrated prognostic tools and risk scores, as well as their potential impact on clinical practice. We aim to provide a comprehensive and clinically oriented synthesis of available evidence in the MS biomarkers field, supporting multifaceted prognostication strategies to improve long-term outcomes in people with MS.

摘要

多发性硬化症(MS)的特征是一系列不同的神经炎症和神经退行性过程,这些过程从疾病的最早阶段就推动疾病进展。这导致了高度异质性的临床病程,需要早期且准确的预后评估:识别可靠的预后生物标志物对于支持治疗决策和指导个性化疾病管理至关重要。在这篇叙述性综述中,我们批判性地审视了当前的MS文献,研究与成人发病型MS疾病进展和不可逆残疾相关的预后因素,重点关注不同的临床、放射学和分子生物标志物。特别关注基线临床和神经影像学因素的预后价值、隐匿性疾病的新兴生物标志物以及与复发活动无关的进展(PIRA)事件。此外,我们讨论了综合预后工具和风险评分的作用,以及它们对临床实践的潜在影响。我们旨在对MS生物标志物领域的现有证据进行全面且以临床为导向的综合,支持多方面的预后策略,以改善MS患者的长期预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7359/12386494/817c43b3556d/ijms-26-07756-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验